Literature DB >> 24850828

Taking a longer term view of cardiovascular risk: the causal exposure paradigm.

Allan D Sniderman1, Peter P Toth2, George Thanassoulis3, Michael J Pencina4, Curt D Furberg5.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24850828     DOI： 10.1136/bmj.g3047

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.

Authors:  Karol M Pencina; George Thanassoulis; John T Wilkins; Ramachandran S Vasan; Ann Marie Navar; Eric D Peterson; Michael J Pencina; Allan D Sniderman
Journal:  J Am Coll Cardiol       Date:  2019-07-09       Impact factor: 24.094

2.  Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial.

Authors:  Charles Christian Adarkwah; Nikita Jegan; Monika Heinzel-Gutenbrunner; Felicitas Kühne; Uwe Siebert; Uwe Popert; Norbert Donner-Banzhoff; Sarah Kürwitz
Journal:  BMC Med Inform Decis Mak       Date:  2016-11-29       Impact factor: 2.796

3.  The effect of a new lifetime-cardiovascular-risk display on patients' motivation to participate in shared decision-making.

Authors:  Nikita Roman A Jegan; Sarah Anna Kürwitz; Lena Kathrin Kramer; Monika Heinzel-Gutenbrunner; Charles Christian Adarkwah; Uwe Popert; Norbert Donner-Banzhoff
Journal:  BMC Fam Pract       Date:  2018-06-09       Impact factor: 2.497

4.  Long-term moderately elevated LDL-cholesterol and blood pressure and risk of coronary heart disease.

Authors:  Peter Ueda; Pablo Gulayin; Goodarz Danaei
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

5.  The Optimizing-Risk-Communication (OptRisk) randomized trial - impact of decision-aid-based consultation on adherence and perception of cardiovascular risk.

Authors:  Charles Christian Adarkwah; Nikita Jegan; Monika Heinzel-Gutenbrunner; Felicitas Kühne; Uwe Siebert; Uwe Popert; Norbert Donner-Banzhoff; Sarah Kürwitz
Journal:  Patient Prefer Adherence       Date:  2019-03-27       Impact factor: 2.711

6.  Cardiovascular risk and aging: the need for a more comprehensive understanding.

Authors:  Ljiljana Trtica Majnarić; Zvonimir Bosnić; Tomislav Kurevija; Thomas Wittlinger
Journal:  J Geriatr Cardiol       Date:  2021-06-28       Impact factor: 3.189

7.  Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments.

Authors:  Maarten J G Leening; M Arfan Ikram
Journal:  PLoS Med       Date:  2018-03-20       Impact factor: 11.069

8.  Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities.

Authors:  Pascal Bovet; Arnaud Chiolero; Fred Paccaud; Nick Banatvala
Journal:  Public Health Rev       Date:  2015-11-25

9.  Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.

Authors:  Peter P Toth; Steven R Jones; Maria Laura Monsalvo; Mary Elliott-Davey; J Antonio G López; Maciej Banach
Journal:  J Am Heart Assoc       Date:  2020-03-02       Impact factor: 5.501
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.